LY2874455 is a potent small-molecule inhibitor that targets fibroblast growth factor receptors (FGFRs), including FGFR1, FGFR2, FGFR3, and FGFR4. It is primarily used in cancer research due to its ability to block FGFR signaling pathways that are often dysregulated in various tumors. This compound shows promise in studies involving cancers with FGFR gene amplifications, mutations, or fusions, such as bladder, gastric, and liver cancers.

Due to its multi-kinase inhibition profile, LY2874455 is employed in preclinical studies to evaluate tumor growth suppression, apoptosis induction, and inhibition of angiogenesis. It is also used to investigate mechanisms of drug resistance in FGFR-driven cancers and to assess the efficacy of combination therapies with other targeted agents or chemotherapeutics. Its application extends to in vitro and in vivo models for validating FGFR as a therapeutic target and for developing biomarkers of response.